Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Matrix Proteolysis.

Baker-Williams AJ, Hashmi F, Budzyński MA, Woodford MR, Gleicher S, Himanen SV, Makedon AM, Friedman D, Cortes S, Namek S, Stetler-Stevenson WG, Bratslavsky G, Bah A, Mollapour M, Sistonen L, Bourboulia D.

Cell Rep. 2019 Aug 13;28(7):1894-1906.e6. doi: 10.1016/j.celrep.2019.07.045.

2.

Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90.

Sager RA, Woodford MR, Backe SJ, Makedon AM, Baker-Williams AJ, DiGregorio BT, Loiselle DR, Haystead TA, Zachara NE, Prodromou C, Bourboulia D, Schmidt LS, Linehan WM, Bratslavsky G, Mollapour M.

Cell Rep. 2019 Jan 29;26(5):1344-1356.e5. doi: 10.1016/j.celrep.2019.01.018.

3.

The multiple facets of the Hsp90 machine.

Blair LJ, Genest O, Mollapour M.

Nat Struct Mol Biol. 2019 Feb;26(2):92-95. doi: 10.1038/s41594-018-0177-7. No abstract available.

4.

Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.

Daugherty M, Daugherty E, Jacob J, Shapiro O, Mollapour M, Bratslavsky G.

Urol Oncol. 2019 Mar;37(3):182.e9-182.e15. doi: 10.1016/j.urolonc.2018.10.021. Epub 2018 Dec 5.

PMID:
30528396
5.

The mTOR Independent Function of Tsc1 and FNIPs.

Sager RA, Woodford MR, Mollapour M.

Trends Biochem Sci. 2018 Dec;43(12):935-937. doi: 10.1016/j.tibs.2018.09.018. Epub 2018 Oct 22.

6.

Extracellular Phosphorylation of TIMP-2 by Secreted c-Src Tyrosine Kinase Controls MMP-2 Activity.

Sánchez-Pozo J, Baker-Williams AJ, Woodford MR, Bullard R, Wei B, Mollapour M, Stetler-Stevenson WG, Bratslavsky G, Bourboulia D.

iScience. 2018 Mar 23;1:87-96. doi: 10.1016/j.isci.2018.02.004. Epub 2018 Mar 23.

7.

Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis.

Sager RA, Woodford MR, Shapiro O, Mollapour M, Bratslavsky G.

Oncotarget. 2018 Apr 24;9(31):22220-22229. doi: 10.18632/oncotarget.25164. eCollection 2018 Apr 24.

8.

Detection and Analysis of Extracellular Hsp90 (eHsp90).

Cortes S, Baker-Williams AJ, Mollapour M, Bourboulia D.

Methods Mol Biol. 2018;1709:321-329. doi: 10.1007/978-1-4939-7477-1_23.

PMID:
29177669
9.

Detecting Posttranslational Modifications of Hsp90.

Sager RA, Woodford MR, Neckers L, Mollapour M.

Methods Mol Biol. 2018;1709:209-219. doi: 10.1007/978-1-4939-7477-1_16.

10.

Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer.

Dushukyan N, Dunn DM, Sager RA, Woodford MR, Loiselle DR, Daneshvar M, Baker-Williams AJ, Chisholm JD, Truman AW, Vaughan CK, Haystead TA, Bratslavsky G, Bourboulia D, Mollapour M.

Cell Rep. 2017 Nov 14;21(7):1883-1895. doi: 10.1016/j.celrep.2017.10.074.

11.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M.

EMBO J. 2017 Dec 15;36(24):3650-3665. doi: 10.15252/embj.201796700. Epub 2017 Nov 10.

12.

Structural and functional basis of protein phosphatase 5 substrate specificity.

Oberoi J, Dunn DM, Woodford MR, Mariotti L, Schulman J, Bourboulia D, Mollapour M, Vaughan CK.

Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9009-14. doi: 10.1073/pnas.1603059113. Epub 2016 Jul 27.

13.

The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.

Woodford MR, Dunn DM, Blanden AR, Capriotti D, Loiselle D, Prodromou C, Panaretou B, Hughes PF, Smith A, Ackerman W, Haystead TA, Loh SN, Bourboulia D, Schmidt LS, Marston Linehan W, Bratslavsky G, Mollapour M.

Nat Commun. 2016 Jun 29;7:12037. doi: 10.1038/ncomms12037.

14.

Targeting Hsp90 in Non-Cancerous Maladies.

Woodford MR, Dunn DM, Ciciarelli JG, Beebe K, Neckers L, Mollapour M.

Curr Top Med Chem. 2016;16(25):2792-804. Review.

PMID:
27072697
15.

Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium: latest scientific and clinical discoveries.

Bratslavsky G, Woodford MR, Daneshvar M, Mollapour M.

Oncotarget. 2016 Mar 29;7(13):15292-8. doi: 10.18632/oncotarget.7733.

16.

Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.

Woodford MR, Dunn D, Miller JB, Jamal S, Neckers L, Mollapour M.

Adv Cancer Res. 2016;129:31-50. doi: 10.1016/bs.acr.2015.09.002. Epub 2015 Oct 23. Review.

PMID:
26916000
17.

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors.

Woodford MR, Truman AW, Dunn DM, Jensen SM, Cotran R, Bullard R, Abouelleil M, Beebe K, Wolfgeher D, Wierzbicki S, Post DE, Caza T, Tsutsumi S, Panaretou B, Kron SJ, Trepel JB, Landas S, Prodromou C, Shapiro O, Stetler-Stevenson WG, Bourboulia D, Neckers L, Bratslavsky G, Mollapour M.

Cell Rep. 2016 Feb 2;14(4):872-884. doi: 10.1016/j.celrep.2015.12.084. Epub 2016 Jan 21.

18.

The dynamic interactome of human Aha1 upon Y223 phosphorylation.

Wolfgeher D, Dunn DM, Woodford MR, Bourboulia D, Bratslavsky G, Mollapour M, Kron SJ, Truman AW.

Data Brief. 2015 Nov 6;5:752-5. doi: 10.1016/j.dib.2015.10.028. eCollection 2015 Dec.

19.

Chromophobe Renal Cell Carcinoma is the Most Common Nonclear Renal Cell Carcinoma in Young Women: Results from the SEER Database.

Daugherty M, Blakely S, Shapiro O, Vourganti S, Mollapour M, Bratslavsky G.

J Urol. 2016 Apr;195(4 Pt 1):847-51. doi: 10.1016/j.juro.2015.10.177. Epub 2015 Nov 10.

PMID:
26555952
20.

c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells.

Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, Morgan RM, Prodromou C, Kron SJ, Panaretou B, Stetler-Stevenson WG, Landas SK, Neckers L, Bratslavsky G, Bourboulia D, Mollapour M.

Cell Rep. 2015 Aug 11;12(6):1006-18. doi: 10.1016/j.celrep.2015.07.004. Epub 2015 Jul 30.

21.

Targeting Hsp90 in urothelial carcinoma.

Chehab M, Caza T, Skotnicki K, Landas S, Bratslavsky G, Mollapour M, Bourboulia D.

Oncotarget. 2015 Apr 20;6(11):8454-73. Review.

22.

Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.

Mol Cell. 2014 Jan 23;53(2):317-29. doi: 10.1016/j.molcel.2013.12.007.

23.

The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.

Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, Yoshida S, Trepel JB, Huang Y, Tatokoro M, Shinohara N, Nonomura K, Neckers L.

Cancer Res. 2013 Dec 1;73(23):7022-33. doi: 10.1158/0008-5472.CAN-13-1156. Epub 2013 Oct 11.

24.

Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.

Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.

Oncotarget. 2013 Jul;4(7):1065-74.

25.

Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.

Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M.

Future Med Chem. 2013 Jun;5(9):1059-71. doi: 10.4155/fmc.13.88. Review.

PMID:
23734688
26.

Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.

Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, Neckers L.

Cell Cycle. 2012 Oct 1;11(19):3649-55. doi: 10.4161/cc.21926. Epub 2012 Aug 30.

27.

Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.

Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, Neckers LM, Trepel JB.

Curr Mol Med. 2012 Nov 1;12(9):1125-41. Review.

28.

Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.

Xu W, Mollapour M, Prodromou C, Wang S, Scroggins BT, Palchick Z, Beebe K, Siderius M, Lee MJ, Couvillon A, Trepel JB, Miyata Y, Matts R, Neckers L.

Mol Cell. 2012 Aug 10;47(3):434-43. doi: 10.1016/j.molcel.2012.05.015. Epub 2012 Jun 21.

29.

Charged linker sequence modulates eukaryotic heat shock protein 90 (Hsp90) chaperone activity.

Tsutsumi S, Mollapour M, Prodromou C, Lee CT, Panaretou B, Yoshida S, Mayer MP, Neckers LM.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2937-42. doi: 10.1073/pnas.1114414109. Epub 2012 Feb 6.

30.
31.

Detecting HSP90 phosphorylation.

Mollapour M, Neckers L.

Methods Mol Biol. 2011;787:67-74. doi: 10.1007/978-1-61779-295-3_5.

PMID:
21898227
32.

Post-translational modifications of Hsp90 and their contributions to chaperone regulation.

Mollapour M, Neckers L.

Biochim Biophys Acta. 2012 Mar;1823(3):648-55. doi: 10.1016/j.bbamcr.2011.07.018. Epub 2011 Aug 10. Review.

33.

Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity.

Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L.

Oncotarget. 2011 May;2(5):407-17.

34.

Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity.

Mollapour M, Tsutsumi S, Truman AW, Xu W, Vaughan CK, Beebe K, Konstantinova A, Vourganti S, Panaretou B, Piper PW, Trepel JB, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2011 Mar 18;41(6):672-81. doi: 10.1016/j.molcel.2011.02.011.

35.

A systematic protocol for the characterization of Hsp90 modulators.

Matts RL, Brandt GE, Lu Y, Dixit A, Mollapour M, Wang S, Donnelly AC, Neckers L, Verkhivker G, Blagg BS.

Bioorg Med Chem. 2011 Jan 1;19(1):684-92. doi: 10.1016/j.bmc.2010.10.029. Epub 2010 Oct 19.

36.

Targeting the dynamic HSP90 complex in cancer.

Trepel J, Mollapour M, Giaccone G, Neckers L.

Nat Rev Cancer. 2010 Aug;10(8):537-49. doi: 10.1038/nrc2887. Review.

37.

Hsp90 phosphorylation, Wee1 and the cell cycle.

Mollapour M, Tsutsumi S, Neckers L.

Cell Cycle. 2010 Jun 15;9(12):2310-6. Epub 2010 Jun 15.

PMID:
20519952
38.

Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.

Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2010 Feb 12;37(3):333-43. doi: 10.1016/j.molcel.2010.01.005.

39.

Quinacrine: New anti-tumor application for an old anti-malaria drug.

Mollapour M, Neckers L.

Cell Cycle. 2010 Jan 15;9(2):228. Epub 2010 Jan 15. No abstract available.

PMID:
20061796
40.

Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain.

Tsutsumi S, Mollapour M, Graf C, Lee CT, Scroggins BT, Xu W, Haslerova L, Hessling M, Konstantinova AA, Trepel JB, Panaretou B, Buchner J, Mayer MP, Prodromou C, Neckers L.

Nat Struct Mol Biol. 2009 Nov;16(11):1141-7. doi: 10.1038/nsmb.1682. Epub 2009 Oct 18.

PMID:
19838189
41.

Presence of the Fps1p aquaglyceroporin channel is essential for Hog1p activation, but suppresses Slt2(Mpk1)p activation, with acetic acid stress of yeast.

Mollapour M, Shepherd A, Piper PW.

Microbiology. 2009 Oct;155(Pt 10):3304-11. doi: 10.1099/mic.0.030502-0. Epub 2009 Jul 16.

PMID:
19608606
42.

Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.

Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee MJ, Gourlay CW, Trepel J, Linehan WM, Neckers L.

Mol Cell Biol. 2009 Aug;29(15):4080-90. doi: 10.1128/MCB.00483-09. Epub 2009 May 26.

43.

The Hsp90/Cdc37p chaperone system is a determinant of molybdate resistance in Saccharomyces cerevisiae.

Millson SH, Nuttall JM, Mollapour M, Piper PW.

Yeast. 2009 Jun;26(6):339-47. doi: 10.1002/yea.1670.

44.

The complex dance of the molecular chaperone Hsp90.

Neckers L, Mollapour M, Tsutsumi S.

Trends Biochem Sci. 2009 May;34(5):223-6. doi: 10.1016/j.tibs.2009.01.006. Epub 2009 Apr 7.

PMID:
19359180
45.

Visualizing the twists and turns of a molecular chaperone.

Neckers L, Tsutsumi S, Mollapour M.

Nat Struct Mol Biol. 2009 Mar;16(3):235-6. doi: 10.1038/nsmb0309-235. No abstract available.

PMID:
19259122
46.

Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37.

Vaughan CK, Mollapour M, Smith JR, Truman A, Hu B, Good VM, Panaretou B, Neckers L, Clarke PA, Workman P, Piper PW, Prodromou C, Pearl LH.

Mol Cell. 2008 Sep 26;31(6):886-95. doi: 10.1016/j.molcel.2008.07.021.

47.

Novel stress responses facilitate Saccharomyces cerevisiae growth in the presence of the monocarboxylate preservatives.

Mollapour M, Shepherd A, Piper PW.

Yeast. 2008 Mar;25(3):169-77. doi: 10.1002/yea.1576. Review.

48.
50.

In the yeast heat shock response, Hsf1-directed induction of Hsp90 facilitates the activation of the Slt2 (Mpk1) mitogen-activated protein kinase required for cell integrity.

Truman AW, Millson SH, Nuttall JM, Mollapour M, Prodromou C, Piper PW.

Eukaryot Cell. 2007 Apr;6(4):744-52. Epub 2007 Feb 9.

Supplemental Content

Loading ...
Support Center